These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19228175)

  • 1. Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder.
    Feltner DE; Harness J; Brock J; Sambunaris A; Cappelleri JC; Morlock R
    CNS Neurosci Ther; 2009; 15(1):12-8. PubMed ID: 19228175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and evaluation of the Daily Assessment of Symptoms - Anxiety (DAS-A) scale to evaluate onset of symptom relief in patients with generalized anxiety disorder.
    Morlock RJ; Williams VS; Cappelleri JC; Harness J; Fehnel SE; Endicott J; Feltner D
    J Psychiatr Res; 2008 Oct; 42(12):1024-36. PubMed ID: 18061206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial.
    Cutler NR; Sramek JJ; Wardle TS; Hesselink JM; Roeschen JK
    Psychopharmacol Bull; 1993; 29(2):303-8. PubMed ID: 7904761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonorganic insomnia in generalized anxiety disorder. 2. Comparative studies on sleep, awakening, daytime vigilance and anxiety under lorazepam plus diphenhydramine (Somnium) versus lorazepam alone, utilizing clinical, polysomnographic and EEG mapping methods.
    Saletu B; Saletu-Zyhlarz G; Anderer P; Brandstätter N; Frey R; Gruber G; Klösch G; Mandl M; Grünberger J; Linzmayer L
    Neuropsychobiology; 1997; 36(3):130-52. PubMed ID: 9313245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder.
    Fresquet A; Sust M; Lloret A; Murphy MF; Carter FJ; Campbell GM; Marion-Landais G
    Ann Pharmacother; 2000 Feb; 34(2):147-53. PubMed ID: 10676820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
    Cutler NR; Sramek JJ; Keppel Hesselink JM; Krol A; Roeschen J; Rickels K; Schweizer E
    J Clin Psychopharmacol; 1993 Dec; 13(6):429-37. PubMed ID: 7907097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.
    Pollack MH; Zaninelli R; Goddard A; McCafferty JP; Bellew KM; Burnham DB; Iyengar MK
    J Clin Psychiatry; 2001 May; 62(5):350-7. PubMed ID: 11411817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients.
    Laakmann G; Schüle C; Lorkowski G; Baghai T; Kuhn K; Ehrentraut S
    Psychopharmacology (Berl); 1998 Apr; 136(4):357-66. PubMed ID: 9600581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder.
    Woelk H; Schläfke S
    Phytomedicine; 2010 Feb; 17(2):94-9. PubMed ID: 19962288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers.
    Bailey JE; Kendrick A; Diaper A; Potokar JP; Nutt DJ
    J Psychopharmacol; 2007 Jan; 21(1):42-9. PubMed ID: 16533865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term comparison of alprazolam, lorazepam and placebo in patients with an anxiety disorder.
    Cohn JB; Wilcox CS
    Pharmacotherapy; 1984; 4(2):93-8. PubMed ID: 6144090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effectiveness of Galphimia glauca vs. lorazepam in generalized anxiety disorder. A controlled 15-week clinical trial.
    Herrera-Arellano A; Jiménez-Ferrer JE; Zamilpa A; García-Alonso G; Herrera-Alvarez S; Tortoriello J
    Planta Med; 2012 Sep; 78(14):1529-35. PubMed ID: 22828921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders].
    Lemoine P; Rouillon F; Pouget D
    Encephale; 1996; 22(6):461-7. PubMed ID: 10901839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
    Rickels K; Pollack MH; Feltner DE; Lydiard RB; Zimbroff DL; Bielski RJ; Tobias K; Brock JD; Zornberg GL; Pande AC
    Arch Gen Psychiatry; 2005 Sep; 62(9):1022-30. PubMed ID: 16143734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study.
    Pollack MH; Roy-Byrne PP; Van Ameringen M; Snyder H; Brown C; Ondrasik J; Rickels K
    J Clin Psychiatry; 2005 Nov; 66(11):1401-8. PubMed ID: 16420077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical assessment of the safety and efficacy of lorazepam, a new benzodiazepine derivative, in the treatment of anxiety.
    Pinosky DG
    J Clin Psychiatry; 1978 Oct; 39(10 Pt 2):24-9. PubMed ID: 30763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo-controlled comparison of the clinical effects of rapid discontinuation of ipsapirone and lorazepam after 8 weeks of treatment for generalized anxiety disorder.
    Mandos LA; Rickels K; Cutler N; Roeschen J; Keppel Hesselink JM; Schweizer E
    Int Clin Psychopharmacol; 1995 Nov; 10(4):251-6. PubMed ID: 8748047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
    Lemoine P; Touchon J; Billardon M
    Encephale; 1997; 23(4):290-9. PubMed ID: 9417395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.